• About
  • Board
  • Expert Index
  • Podcasts
  • News
  • Sign up
  • Contact

Visit

VJHemOnc - Hematological Oncology
  • Home
  • Diseases
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myeloproliferative Neoplasms
    Myelodysplastic Syndromes
    Others
    View all Diseases
  • Trials
    • MUK Nine b
    • TEAMM
    • MUK Seven
    • PERSPECTIVE
    • Hokusai VTE-Cancer Study
    • ZUMA-3
    • UKALL14
    • MEDI4736
    • BMS-936558
    • BRIGHT AML1019
    • View all trials
  • Medicines
    • Levofloxacin
    • Edoxaban
    • AMG 330
    • Glasdegib
    • IMGN779
    • Avapritinib
    • Cirmtuzumab
    • Pegfilgrastim
    • Procarbazine
    • Filanesib
    • View all medicines
  • Topics
    • Disease Biology
    • Pharmacy
    • Surgery
    • Treatment
    • Communication
    • Perspectives
    • Policy
    • Psycho-Oncology
    • Supportive Care
    • Transplantation
    • View all topics
  • Conferences
    • HOPA 2018
    • EBMT 2018
    • iwAL 2018
    • UKONS 2017
    • ASH 2017
    • MPN Advances Day 2017
    • NCRI 2017
    • ESH 2017
    • Myeloma 2017
    • BOPA 2017
    • View upcoming conferences
    • View previous conferences
  • Features
    • About
    • Board
    • Expert Index
    • Podcasts
    • News
    • Sign up
    • Contact
3:35
The role of MRD in ALL: what defines a complete response?
Bijal Shah
1:25
The diagnosis of early T-cell precursor (ETP) ALL
Bijal Shah
2:56
Molecular subtypes of ALL: coming to a consensus
Bijal Shah
2:37
Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response
Naval Daver
2:05
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
Naval Daver
3:31
Update on checkpoint inhibitor therapy for AML: salvage, frontline & azacitidine combination
Naval Daver
3:14
Targeting sonic hedgehog signaling in AML
Jorge Cortes
6:03
Genomics and acute leukemia management: artificial intelligence, deep learning & pre-leukemic clones
Ari Melnick et al.
8:13
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Ari Melnick et al.
11:57
The evolving genomic landscape of ALL: molecular genetics, profiling and classification
Anjali Advani et al.
10:31
Recent subtypes of ALL: Ph-like ALL and ETP ALL
Anjali Advani et al.
1:30
Determining the progression of SMM using predictive biomarkers
Irene Ghobrial
3:33
Next steps in gaining CLARITY on CLL
0:57
What can we learn about CLL by studying environmental stimuli?
Francesco Forconi
1:33
Understanding the mechanisms of venetoclax and ibrutinib resistance
Constantine Tam
1:11
Results and rational behind breakthrough therapy-designated E-selectin antagonist for AML
Daniel DeAngelo
  • 1
  • 2
  • Next
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Please enter your details if you would like to receive the latest Hemonc news and updates

Continue
Video channels
  • Chronic Lymphocytic Leukemia
  • Follicular Lymphoma
  • Multiple Myeloma
  • B-Cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Chronic Myeloid Leukemia
  • Amyloidosis
  • Hodgkin Lymphoma
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Terms of Use
  • Terms of Use
  • Privacy Policy